Liquid biopsy techniques, such as circulating tumour DNA (ctDNA) analysis, could be explored to monitor LSM2 expression and its molecular network, further enhancing diagnostic capabilities for glioma (34, 35). Here, LSM2 is linked to central nervous system cancer.